# Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

> **NCT07716046** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 240 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer
- Hormone Receptor-positive Breast Cancer
- HR+/HER2+ Breast Cancer

## Interventions

- **DRUG:** Fulvestaciclib
- **BIOLOGICAL:** Trastuzumab
- **BIOLOGICAL:** Pertuzumab
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Taxane

## Key facts

- **NCT ID:** NCT07716046
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2030-08-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716046, "Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07716046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*